Net revenue declined 31% year-over-year for Jan–Sep 2025, with improved EBITDA and EBIT losses. Cash reserves increased, but funding remains critical as the board warns of insufficient liquidity for year-end. Leadership transition and R&D progress in ADCs highlighted.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.